AR and breast carcinoma: Novel bis(hydroxymethyl)alkanoate curcuminoid derivative 14 (Figure 2) [66] exhibited excellent inhibitory activity against human breast cancer cell lines MCF-7 (IC50 6.1 ± 0.5 μM), T47D (IC50 19 ± 1 μM), HER-2+ breast cancer SKBR3 (IC50 6.4 ± 0.4 μM), BT474 (IC50 6.2 ± 0.9 μM), MDA-MB-453 (IC50 4.0 ± 0.3 μM), TNBC HS-578T (IC50 8.0 ± 0.3 μM), MDA-MB-157 (IC50 9.2 ± 0.1 μM), MDA-MB-468 (IC50 6.1 ± 0.5 μM), AR+ breast cancer MDA-MB-453 (IC50 4.0 ± 0.3 μM), human colon cancer HCT-116 (IC50 3.9 ± 0.3 μM/72 h) and classical prostate cancer PC-3 (IC50 3.90 ± 0.08 μM/72 h) cell lines.